Overdose deaths decline, a cross-species kidney transplant, poems help conservation efforts: Catch up on the day's stories
Here's what else you might have missed during your busy day:
1️⃣ Unprecedented drop: US drug overdose deaths in 2024 hit the lowest they've been in five years, according to a new estimate from the federal government. Last month, the Trump administration laid out its drug policy priorities for 2025, but cuts to funding for agencies like the CDC could threaten the progress made.
2️⃣ Costs an arm and a leg: Home-renovation professionals tell CNN that they've been bracing for higher prices due to tariffs. From Tuscan tilework to Chinese refrigerators, the US imports billions of dollars worth of home goods from around the globe. Here's how tariffs are threatening this booming industry.
3️⃣ A shot at living: In the US, nearly 90,000 people are on the waiting list for a kidney transplant. The typical wait is three to five years, but that time was doubled for Tim Andrews, who also has a rare blood type. Now, Andrews is thriving as one of only a handful of patients to undergo an experimental cross-species transplant of a kidney from a genetically modified pig.
4️⃣ Poems & porpoises: The Yangtze finless porpoise — a smaller dolphin-like creature — has faced extreme declines in numbers in the past four decades. A research team in China used ancient poems to find clues as to where the animals historically thrived, to help with conservation efforts.
5️⃣ 'A magical place': This extraordinary desert country aims to be a major tourist destination by 2030. In January 2023, its government introduced changes, making a once-challenging-to-obtain visa guaranteed upon arrival after paying fees. As a result, tourism has significantly increased.
GET '5 THINGS' IN YOUR INBOX
CNN's 5 Things newsletter is your one-stop shop for the latest headlines and fascinating stories to start and end your busy day. Sign up here. ⌚Tiny time: The world's thinnest tourbillon watch — which costs $678,000 — weighs just 43 grams and squeezes intricate mechanisms into a timepiece only 1.85mm thick.
• Trump's embrace of Syria could reshape the Middle East• First on CNN: New book reveals how Biden's inner circle kept Cabinet from him in final two years of presidency• Defense cross-examination of Cassie Ventura will begin Thursday in Sean 'Diddy' Combs' trial
🍟 That's how many people McDonald's says it plans to hire this summer. It's the fast-food chain's biggest employment initiative in five years.
☠️ Fossil find: A cicada pressed into rocks approximately 47 million years ago is so well preserved that you can see the veins in its wings. The discovery gives scientists new hints about how the bug evolved.
🎤 Speaking out: Robert De Niro used his acceptance speech at the Cannes Film Festival to criticize President Donald Trump, calling him a 'philistine president.'
📺 What did ESPN name its new flagship streaming service?A. Disney+ SportsB. Sports on DemandC. ESPND. Sports Now⬇️ Scroll down for the answer.
🤩 Surprise! Celine Dion made an unexpected video appearance at Eurovision, 37 years after winning the contest. The Canadian-born star delivered a heartfelt message to contestants, organizers and viewers at the semi-final event.
👋 We'll see you tomorrow.🧠 Quiz answer: C. ESPN. 'There's power in our name, and there's trust in our name,' network chairman James Pitaro said on the decision to stick with the company's four letters.📧 Check out all of CNN's newsletters.
5 Things PM is produced by CNN's Chris Good, Meghan Pryce and Kimberly Richardson.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
The sober-curious generation? This map shows where Gen Z is reshaping U.S. drinking habits.
Gen Z is the sober-curious generation. Between 2011 and 2023, the number of adults aged 18 to 24 who drank alcohol dropped by 8 percentage points, according to survey data from the Centers for Disease Control and Prevention. Consumption among 25- to 34-year-olds has also fallen 5 percentage points over the past decade, making young adults the driving force behind America's diminishing alcohol consumption. Gen Z is driving the shift away from drinking. Even young people who do drink do so less frequently than previous generations. Nearly two-thirds of 18- to 34-year-olds say one to two drinks a day is bad for their health, reflecting changing attitudes toward drinking. These days, drinking less doesn't mean sacrificing a social life, though. Bars and liquor stores are catering to a growing demand for mocktails and zero-proof alcohol. Data from Eventbrite shows a 92% rise in sober-curious events across the country over the past year. These include everything from morning dance parties (20% rise) to DJ'd events with coffee instead of alcohol (478% rise). Advertisement Yahoo used data from Behavioral Risk Factor Surveillance System to examine the evolving drinking culture among young adults in the U.S. The map data is based on surveys conducted between 2011-2012 and 2022-2023.
Yahoo
3 minutes ago
- Yahoo
CVS unit must pay $290 million in drug whistleblower lawsuit, judge rules
A federal judge ordered CVS Health's pharmacy benefit manager unit to pay $289.9 million in damages and penalties after it overcharged Medicare for prescription drugs. In a Tuesday decision, Chief Judge Mitchell Goldberg in Philadelphia federal court tripled to $285 million the damages he had ordered CVS Caremark to pay in June, citing the federal False Claims Act. He added a $4.87 million civil fine. Goldberg rejected CVS' request to pay less, saying that while CVS Caremark was liable for only two years of overbilling, evidence at trial "made clear that the fraud was financially motivated, not the result of some innocent or mistaken belief." CVS, based in Woonsocket, said on Wednesday it plans to appeal. Last month, a Manhattan federal judge ordered CVS' Omnicare unit to pay $948.8 million in a separate whistleblower lawsuit alleging fraudulent billing. CVS plans to appeal that judgment. Goldberg presided in March over a non-jury trial in the whistleblower case brought by Sarah Behnke, a former head actuary for Medicare Part D at Aetna. She accused CVS Caremark of having caused health insurers such as Aetna to submit inflated claims since 2010 to the Centers for Medicare and Medicaid Services (CMS), while pharmacies such as Rite Aid and Walgreens WBA.O were paid less. CVS argued that the original $95 million in damages was substantial, and punitive damages should be limited to $95 million. But the judge said CVS Caremark's fraud not only financially harmed the government, but diminished public confidence in it. "CMS relies on companies like Caremark to truthfully and accurately report Part D drug prices," he wrote. "Caremark's conduct broke CMS's trust, and as a result, the public's trust in CMS." Behnke sued in 2014. CVS bought Aetna four years later. The False Claims Act lets whistleblowers sue on behalf of the government and share in recoveries, typically 15% to 30%. This article originally appeared on The Providence Journal: Judge: CVS Caremark overcharged Medicare for prescription drugs Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
4 minutes ago
- Medscape
High Adherence to Dupilumab in Chronic Rhinosinusitis
TOPLINE: An analysis of a real-world US practice revealed that a substantial proportion of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who initiated dupilumab remained adherent at 12 months. Among those who discontinued therapy, over 40% resumed treatment within a short timeframe. METHODOLOGY: Researchers used real-world administrative claims and clinical data to analyze treatment patterns of 3318 patients (mean age, 47.1 years; 54.4% men) with CRSwNP who initiated dupilumab between June 2019 and December 2021. Persistence with dupilumab was defined as the interval from treatment initiation to either the end of a 60-day gap without a refill or a switch to another CRSwNP biologic (omalizumab or mepolizumab). Patients were considered adherent to dupilumab if they had a medication possession ratio ≥ 0.8 during the 12-month follow-up period. TAKEAWAY: Persistence rates among patients on dupilumab were 84.9% and 69.5% at 6 and 12 months, respectively, with an average follow-up duration of 375.6 days. Of 913 patients who discontinued dupilumab, 366 reinitiated the treatment after a median of 1.2 months, with reinitiation probabilities of 35.5% and 43.3% at 6 and 12 months, respectively. Treatment adherence was 75.2%, with a high mean medication possession ratio of 1.06. IN PRACTICE: 'Future studies examining discontinuation reasons and persistence patterns across type 2 comorbidity and AERD [aspirin-exacerbated respiratory disease] subgroups would enhance our understanding of dupilumab use in CRSwNP patients,' the authors of the study wrote. SOURCE: Zhixiao Wang, PhD, with Regeneron Pharmaceuticals, Inc., Tarrytown, New York, was the corresponding author of the study, which was published online on August 15 in The Journal of Allergy and Clinical Immunology: Global. LIMITATIONS: Reasons for dupilumab discontinuation could not be determined, dispensing for comorbid asthma or atopic dermatitis was not captured, and the 1-year continuous enrollment requirement may have introduced selection bias. In addition, the study findings may not be generalizable to other publicly insured or uninsured patients, and reliance on a subjective gap definition in claims data may have resulted in imprecise records of discontinuation timing. DISCLOSURES: The study was funded by Sanofi and Regeneron Pharmaceuticals, Inc. Three authors reported being employees of Regeneron Pharmaceuticals, Inc., and two reported being employees of Sanofi; all five may hold stock or stock options in their respective companies. Three additional authors reported being employees of Analysis Group. One author reported serving on the advisory board and speakers bureau for both Sanofi and Regeneron Pharmaceuticals, Inc. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
